Clinical Trial Update: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating a subcutaneous fixed-dose combination of nivolumab and relatlimab in previously untreated metastatic or unresectable me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Relatlimab (relatlimab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING